What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

1. NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation.Frontiers in immunology · 2026
   Review
2. Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation.Drug delivery and translational research · 2025
   Review
3. Apelin Controls Angiogenesis-Dependent Glioblastoma Growth.International journal of molecular sciences · 2020
   Article
4. What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.EMBO molecular medicine · 2019
   Article

Corrections and comments

• Comment on
  Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.2019

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as